Home › Research › Drug development
Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications
Moreira RO, Campos SC, Soldera AL.. Diabetes/metabolism research and reviews, 2013-07-18
This paper has been retracted. The record we hold marks it as a retracted publication. Check the original source below for the retraction notice before relying on anything it reports.
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's Disease (AD) is the most common cause of dementia worldwide. Type 2 Diabetes Mellitus (T2DM) is a disease characterized by insulin resistance (IR) and progressive β cell failure, and affected individuals are at increased risk to develop several forms of cognitive dysfunction, including AD. Different mechanisms have already been identified linking visceral obesity, IR and AD. Insulin resistance is associated with a decrease in glucose uptake by neurons, an increase in Amyloid β production and secretion, in the formation of senile plaques, and also in tau protein phosphorylation. Other mechanisms also include a decrease in Insulin Degrading Enzyme (IDE) activity and an increase in oxidative stress secondary to hyperglycemia. Taken together, these mechanisms suggest that drugs used to ameliorate hyperglycemia and IR may also have beneficial effects in diabetic patients with AD. Indeed, manuscripts investigating the effects of metformin, thiazolinediones, leptin, GLP-1 therapies, insulin and bariatric surgery in cognition and AD have been published with very promising results, and may indicate an alternative approach for these patients. This article is protected by copyright. All rights reserved.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Moreira, R. O., Campos, S. C., & Soldera, A. L. (2013). Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications. Diabetes/metabolism research and reviews. https://doi.org/10.1002/dmrr.2442
Vancouver
Moreira RO, Campos SC, Soldera AL. Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications. Diabetes/metabolism research and reviews. 2013. doi:10.1002/dmrr.2442. PMID: 23868462.
BibTeX
@article{moreira2013-23868462,
author = {Moreira, R. O. and Campos, S. C. and Soldera, A. L.},
title = {{Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications}},
journal = {Diabetes/metabolism research and reviews},
year = {2013},
doi = {10.1002/dmrr.2442},
pmid = {23868462},
url = {https://doi.org/10.1002/dmrr.2442}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Type 2 Diabetes Mellitus (T2DM) is a disease characterized by insulin resistance (IR) and progressive β cell failure, and affected individuals are at increased risk to develop several forms of cognitive dysfunction, including AD.
- Insulin resistance is associated with a decrease in glucose uptake by neurons, an increase in Amyloid β production and secretion, in the formation of senile plaques, and also in tau protein phosphorylation.
- Taken together, these mechanisms suggest that drugs used to ameliorate hyperglycemia and IR may also have beneficial effects in diabetic patients with AD.
- Indeed, manuscripts investigating the effects of metformin, thiazolinediones, leptin, GLP-1 therapies, insulin and bariatric surgery in cognition and AD have been published with very promising results, and may indicate an alternative approach for these patients.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 10/100
Retracted — do not rely on it. It scored 10 on the same rubric, which is below the 16 cap we apply to non-peer-reviewed sources. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 6 of the 62 points we could judge it on, which is 10 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Diabetes/metabolism research and reviews) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 0 / 10 | Retracted — do not rely on it. PubMed indexes it as a Retracted Publication. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23868462) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 6 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 6 of the 62 points we could judge it on is 10 out of 100. |
| Total | 10 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “apply”
2 studies in the library carry the topic tag “apply”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.